Publikationen in Zusammenarbeit mit Forschern von Brigham and Women's Hospital (42)

2024

  1. Author Correction: Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement (Nature Reviews Endocrinology, (2023), 19, 12, (722-740), 10.1038/s41574-023-00886-5)

    Nature Reviews Endocrinology

2023

  1. A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry

    Breast cancer research : BCR, Vol. 25, Núm. 1, pp. 93

  2. A second update on mapping the human genetic architecture of COVID-19

    Nature

  3. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement

    Nature Reviews Endocrinology, Vol. 19, Núm. 12, pp. 722-740

  4. Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers

    Pituitary, Vol. 26, Núm. 5, pp. 583-596

2021

  1. Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk

    Journal of the National Cancer Institute, Vol. 113, Núm. 3, pp. 329-337

  2. Consensus on diagnosis and management of Cushing's disease: a guideline update

    The lancet. Diabetes & endocrinology, Vol. 9, Núm. 12, pp. 847-875

  3. Granulomas in Dermatopathology: Principal Diagnoses - Part 1

    Actas Dermo-Sifiliograficas, Vol. 112, Núm. 8, pp. 682-704

  4. Granulomas in Dermatopathology: Principal Diagnoses — Part 2

    Actas Dermo-Sifiliograficas, Vol. 112, Núm. 8, pp. 705-724

  5. Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?

    Journal of the Endocrine Society, Vol. 5, Núm. 3

2020

  1. Multidisciplinary management of acromegaly: A consensus

    Reviews in Endocrine and Metabolic Disorders, Vol. 21, Núm. 4, pp. 667-678

2019

  1. Author Correction: Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (Nature Genetics, (2019), 51, 3, (414-430), 10.1038/s41588-019-0358-2)

    Nature Genetics

  2. Dapagliflozin and cardiovascular outcomes in type 2 diabetes

    New England Journal of Medicine, Vol. 380, Núm. 4, pp. 347-357

  3. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628

  4. Erratum to: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (Nature Communications, (2018), 9, 1, (4616), 10.1038/s41467-018-06863-1)

    Nature Communications

  5. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing

    Nature Genetics, Vol. 51, Núm. 3, pp. 414-430

  6. Genome-wide association study of germline variants and breast cancer-specific mortality

    British Journal of Cancer, Vol. 120, Núm. 6, pp. 647-657

  7. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

    The Lancet, Vol. 394, Núm. 10204, pp. 1169-1180

  8. Treatment of Diabetes in Older Adults: An Endocrine Society

    Journal of Clinical Endocrinology and Metabolism, Vol. 104, Núm. 5, pp. 1520-1574

2018

  1. Alirocumab and cardiovascular outcomes after acute coronary syndrome

    New England Journal of Medicine, Vol. 379, Núm. 22, pp. 2097-2107